Phytopharm shares advance on strategic review update

Development stage pharmaceuticals group Phytopharm has unveiled an update on its on-going strategic review which was initiated following the announcement of headline results from its Phase II clinical trial of Cogane in Parkinson's disease.

Development stage pharmaceuticals group Phytopharm has unveiled an update on its on-going strategic review which was initiated following the announcement of headline results from its Phase II clinical trial of Cogane in Parkinson's disease.

On February 18th, Phytopharm announced that analysis of headline results from its Phase II clinical trial of Cogane in Parkinson's disease indicated that the drug had not demonstrated clinically meaningful efficacy.

In its most recent update, the company said that a full analysis of the complete dataset had now been completed confirming the initial view that no efficacy was demonstrated in the primary or secondary endpoints measured in the study.

"As a result of these findings, no further research and development expenditure will be committed and a staff reduction and cost saving programme has been initiated," the group said.

The group added that it had also initiated a review of the strategic options available to the company, which included the review of a number of merger and acquisition opportunities.

Exploratory discussions had been held with a number of parties, the group added.

Phytopharm's share price was up 3.33% to 1.55p at 10:29 on Tuesday.

MF

Recommended

Marks & Spencer shares look cheap – should you buy in?
Retail stocks

Marks & Spencer shares look cheap – should you buy in?

Marks & Spencer shares have been a disappointment for investors for two decades. But with the company now on something of a comeback, Rupert Hargreave…
25 May 2022
The Federal Reserve wants markets to fall – here’s what that means for investors
Stockmarkets

The Federal Reserve wants markets to fall – here’s what that means for investors

The Federal Reserve’s primary mandate is to keep inflation down, and lower asset prices help with that. So, asks Dominic Frisby – just how low will st…
25 May 2022
Four high-quality US stocks to give shelter from the storm
Share tips

Four high-quality US stocks to give shelter from the storm

Professional investor Timothy Parton of the JPMorgan American Investment Trust picks four solid US stocks to buy now.
24 May 2022
Three undervalued mid-cap stocks with attractive prospects
Share tips

Three undervalued mid-cap stocks with attractive prospects

Professional investor Katen Patel of the JPMorgan Mid Cap Investment Trust picks three fast-growing mid-cap stocks to buy now.
24 May 2022

Most Popular

The world’s hottest housing markets are faltering – is the UK next?
House prices

The world’s hottest housing markets are faltering – is the UK next?

As interest rates rise, house prices in the world’s most overpriced markets are starting to fall. The UK’s turn will come, says John Stepek. But will …
23 May 2022
Everything is collapsing at once – here’s what to do about it
Investment strategy

Everything is collapsing at once – here’s what to do about it

Equity and bond markets are crashing, while inflation destroys the value of cash. Merryn Somerset Webb looks at where investors can turn to protect th…
23 May 2022
The Federal Reserve wants markets to fall – here’s what that means for investors
Stockmarkets

The Federal Reserve wants markets to fall – here’s what that means for investors

The Federal Reserve’s primary mandate is to keep inflation down, and lower asset prices help with that. So, asks Dominic Frisby – just how low will st…
25 May 2022